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Cohort Studies (and Skin Cancer)
Never Come Alone
Joris A.C. Verkouteren1, Robert J.T. van der Leest1 and Tamar Nijsten1
A previous keratinocyte carcinoma is probably the strongest predictor of
developing new keratinocyte carcinomas, which makes these patients an
interesting population for prevention interventions. Investing in large
cohort studies and consortia might increase the validity of observational
findings and should stimulate scientists to investigate the underlying mechanisms
in detail.
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It is well known that the risk of a
subsequent cutaneous malignancy is
increased in patients with a previous
keratinocyte carcinoma (KC). A recent
meta-analysis showed that 29% of
patients with a history of basal cell
carcinoma (BCC) developed a subse-
quent BCC and 4% a subsequent squa-
mous cell carcinoma (SCC), whereas
13% of patients with a history of SCC
developed a subsequent SCC and 16% a
subsequent BCC (Flohil et al., 2013).
The majority of studies on multiple cuta-
neous malignancies calculated risks of a
subsequent or second primary skin
cancer but did not calculate risks of
additional skin cancers. In this issue,
Ade`le Green’s research group selected
a cohort of 1,191 white-skinned
Australian residents from their Nambour
skin cancer prevention trial, without
KC, before or at the start of this trial,
to determine the proportion who
developed a BCC exclusively, SCC, or
both (Keim et al., 2014). The original
cohort consisted of 1,621 residents of
the subtropical city Nambour, who
were selected at random in 1986, and
therefore the cohort reflects a general
population sample from Australia
followed prospectively between 1992
and 2007. Besides the type of skin
cancer, the investigators also assessed
anatomic site distributions and other
clinical features such as pigmentary
characteristics and signs of actinic
damage. This study demonstrated that
about 21% of the study population
developed a first KC and 47% of this
group developed at least a second KC.
The majority of this latter group deve-
loped exclusively BCCs (56%), 28%
developed both, 16% developed SCCs
exclusively, with age as the most impor-
tant predictor of increasing incidence
rates (Keim et al., 2014). Participants
who developed SCC exclusively were
the most distinct group, because they
had significantly higher prevalences of
easily sunburned skin, propensity to tan
without burning, and freckling of the
back than did the BCC only and mixed
groups. The skin, eye, and hair color
characteristics showed no significant
differences among the three groups. In
those with BCCs exclusively or both
BCC and SCC, the head and neck area
were the predominant sites of develop-
ment, whereas in the SCC only group
the limbs were the predominant sites of
development. These differences may be
the result of differences in UVR expo-
sure or genetic susceptibilities, and they
suggest different tumor biologies.
Major strengths of this study are 16
years of follow-up, a clear case defini-
tion (i.e., histopathologically confirmed
tumors), full-body skin examinations,
and detailed information on clinical
features. However, the main limitation
lies in the small sample of patients with
multiple cutaneous malignancies,
especially the group who developed
SCCs exclusively (n¼28). Small sample
sizes result in wide confidence intervals
and a possible type II error (i.e., no
power calculation shown). Although
the cohort was followed for 16 years,
the study population was young (mean
age 46 years) at enrollment, suggesting
that the majority of the patients had
not yet reached the age in which the
incidence of cutaneous malignancy is
highest.
Actinic neoplasia syndrome
Martin Weinstock coined the term ‘‘acti-
nic neoplasia syndrome’’ to emphasize
that cutaneous (pre-)malignancies are
not a single event but often reflect a
field dysplasia from which patients suf-
fer chronically (Weinstock et al., 2009).
After the 1992 landmark study on this
subject (Karagas et al., 1992), many
observational studies of different
populations demonstrated that almost
half of patients with cutaneous
malignancy will develop at least a
second KC, and even more will show
other signs of chronic actinic skin
damage (e.g., actinic keratosis, solar
elastosis) due to the relatively high
levels of acute, intermittent, and/or cu-
mulative UVR exposure during their
lives. Therefore, a previous cutaneous
malignancy is probably the strongest
predictor of developing subsequent
malignancies, making this an interesting
population for studies of prevention
intervention. One might argue that
the occurrence of multiple malignancies
might pose a greater problem to both
patients and health-care systems
compared with disease progression or
recurrence.
The benefits of primary prevention
programs should become evident only
after decades (Staples et al., 1998). Even
though people become more and more
aware of the harmful effects of UVR,
they do not seem to change their attit-
ude toward it (i.e., knowledge–behavior
gap; Ma et al., 2007). For now, it seems
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that primary prevention is not meeting
its expectations, as the incidence of skin
cancer continues to increase worldwide,
with the possible exception of Australia,
which has a highly active public edu-
cation campaign (Lomas et al., 2012).
As primary prevention falls short, secon-
dary prevention offers a good alternative
strategy. This prevention method will be
most successful when high-risk popu-
lations are defined and screening strate-
gies for specific patient groups
constructed. Well-calibrated, discrimi-
nating, and validated prediction models
could provide physicians with a tool to
find high-risk patients, such as patients
with histories of skin cancer, and give
them appropriate right follow-up and
tailored instructions. If there indeed
exists a type-specific skin cancer
susceptibility, as suggested by Keim
et al. (2014), different prediction models
should be developed, combining
environmental, phenotypic, and geno-
typic risk factors. However, there also
exists a significant group of patients who
develop both BCCs and SCCs, which is
not surprising, as they share many risk
factors (Figure 1). Although the risk factor
profiles of the different cutaneous (pre-
)malignancies are well documented, the
extent to which these risk factors are
applicable to subsequent tumors is not
certain. On the basis of Rothman’s suffi-
cient-component cause model, it could
be argued that the contribution of the
conventional risk factors for a first event
is not applicable to subsequent events,
defined as the index event bias
(Dahabreh and Kent, 2011). In recent
decades, huge steps have been made in
understanding the genetic predisposition
(germline and somatic mutations) for
BCC and to a lesser extent for SCC and
actinic keratosis. However, our genetic
understanding of these very common
keratinocyte malignancies lags behind
melanoma. Except for a few candidate
gene studies and a genome-wide
association study, no studies have
investigated the common or rare
genetic variants found in patients with
multiple keratinocyte malignanies. There
is hope, because an international
consortium has been established to
explore the genetics of patients with
multiple skin cancers and to develop
prediction models that include genetic
variation.
Prospective follow-up studies
As dermato-epidemiologists, we noticed
another important element in this study
(Keim et al., 2014), which is the enor-
mous return on investment seen in this
prospective Nambour skin cancer study.
Clinical epidemiology includes experi-
mental and observational research that
might aid our understanding of diseases
through a quantitative approach of
clinical problems. The Nambour skin
cancer trial started as an experimental
study (a randomized field trial) but
extended its follow-up as a prospective
cohort study. The advantages of that
type of design are the possibility of
calculating risk measures (absolute and
relative risk) and a relatively low risk of
bias compared with other observational
designs. The classical argument against
cohort studies is that they are too
expensive, but large (population-based)
prospective cohort studies such as the
Clinical Implications
 Development of multiple skin cancers may indicate the beginning of
chronic disease.
 Basal cell carcinoma and squamous cell carcinoma do have risk factors in
common, but they are distinct entities.
Mechanistic studies will offer better understanding of the etiopathogen-
esis of skin cancer.
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Figure 1. Risk factor profiles of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). BCNS, basal cell nevus syndrome; EV, epidermodysplasia
verruciformis; XP, xeroderma pigmentosum.
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Nambour Skin Cancer Study, the
Rotterdam Study, Nurses’ Health Study,
the Health Professionals Follow-up
Study, and the PUVA Follow-up Study
have a tremendous scientific return on
investment in many diseases, including
skin cancer (Nan et al., 2011; Stern and
Study PF-U, 2012; Hofman et al., 2013;
Keim et al., 2014). We are strong
advocates of investing in well-designed
and large cohort studies (including
drug or disease specific registries), but
at the same time we encourage
investigators to form a consortia to
increase sample size and to replicate
each other’s findings. Collaborative
efforts increase the validity of the
observational findings and should
stimulate laboratory scientists even
more strongly to investigate the
underlying mechanisms in detail.
In conclusion, good research raises
more questions than it answers, and it
lifts the bar for scientific progress.
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Clonal Analysis of B-Cell Response
in Pemphigus Course: Toward More
Effective Therapies
Giovanni Di Zenzo1 and Giovanna Zambruno1
In this issue, Hammers et al. report the first longitudinal study of B-cell responses
in pemphigus vulgaris. They show persistence of the same sets of anti-desmoglein
3 (Dsg3) B-cell clones over time in two patients with active disease, suggesting that
escape from tolerance is not a frequent event. In addition, the disappearance of
anti-Dsg3 B-cell clones in two patients during long-term rituximab-induced
remission supports the therapeutic potential of rituximab.
Journal of Investigative Dermatology (2015) 135, 651–654. doi:10.1038/jid.2014.499
Pemphigus vulgaris (PV) is a paradigma-
tic autoantibody-mediated autoimmune
disease caused by anti-desmoglein 3
(Dsg3) and Dsg1 antibodies that
induce loss of keratinocyte adhesion,
leading to blister formation. The crucial
role of anti-Dsg antibodies in PV is
supported by a large body of evidence
including the following: (1) correlation
of disease activity with anti-Dsg anti-
body titers, (2) development of pemphi-
gus-like lesions in neonatal mice by
passive transfer of anti-Dsg IgG from
PV patients, (3) the PV-like phenotype
manifested by Dsg3 knockout mice, and
(4) the PV-like disease phenotype, with
persistent anti-Dsg3 autoantibody pro-
duction, developed by immunodeficient
mice following adoptive transfer of
splenocytes from Dsg3 knockout mice
immunized with murine Dsg3 (Amagai,
2008; Amagai and Stanley, 2012).
Two major clinical variants of PV are
distinguished: 1) mucosal-dominant PV,
characterized by lesions localized to
mucosal tissues and the presence of
autoantibodies against Dsg3, and 2)
mucocutaneous PV (mcPV), affecting
both skin and mucosae and presenting
with autoantibodies against both Dsg3
and Dsg1. The disease runs a progres-
sive and potentially fatal course in the
absence of systemic treatment, which
mainly relies on corticosteroids com-
bined with steroid-sparing immuno-
suppressive drugs, such as azathioprine
and mycophenolate mofetil. Among
second-line therapies, the B cell–
depleting anti-CD20 antibody rituximab
has emerged as a major option for
steroid-resistant disease or when there
are contraindications or severe adverse
effects with conventional therapies.
The remarkable efficacy and acceptable
side-effect profile of rituximab have
favored its increasing use and the
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